On March 25, 2026, Exicure, Inc. (Nasdaq: XCUR) announced its financial results for the year ended December 31, 2025. The company reported a net loss of $4.9 million, a significant improvement compared to a net loss of $9.7 million for the previous year. This reduction in loss was primarily attributed to a $6.0 million gain from the early termination of a lease, which offset increased operating expenses following the acquisition of GPCR Therapeutics USA Inc. The company’s cash and cash equivalents stood at $3.7 million as of December 31, 2025, down from $12.5 million in 2024, raising concerns about liquidity. Exicure indicated that its current liquidity may not be sufficient to fund operations for the next 12 months, necessitating additional financing to support ongoing operations and strategic alternatives. The report also highlighted a substantial increase in research and development expenses, which reached $3.3 million for the year, reflecting the company's commitment to advancing its therapeutic programs. General and administrative expenses also rose to $6.8 million, up from $5.4 million in the prior year, driven by costs associated with the acquisition and integration of GPCR USA. The company is exploring strategic alternatives to maximize stockholder value amidst these financial challenges.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.